Thursday, January 7, 2016
Guardant Health Gains $100M
Redwood City-based Guardant Health, which is developing cell-free, DNA liquid biopsy technology for cancer testing via blood samples, said today that it has raised $100M in a Series D funding. The funding was led by OrbiMed Advisors, and also included Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar, Formation 8, and Heritage Group. The company says it has now raised nearly $200M in total. Guardant Health is led by Helmy Eltoukhy. More information »